OnCo
trialsTrialPositive

KEYNOTE-204

In KEYNOTE-204, PD-1 blockade beat the CD30 ADC head to head in relapsed Hodgkin lymphoma.

PFS 13.2 vs 8.3 months (HR 0.65); approved October 2020 for relapse after ≥1 line in adults and ≥2 lines in children.

Setting
Relapsed/refractory classical Hodgkin lymphoma: pembrolizumab vs brentuximab vedotin
Phase
Phase 3
Sponsor
Merck
Registry
Headline result
PFS 13.2 vs 8.3 months, HR 0.65.
Reported
2020
Enrolled
304

Outcomes

1top
In plain words
What these results mean for people, not percentages
304 people took part
Progression-free survival (median)primarysurrogate endpoint
  • Median 13.2 vs 8.3 months with Pembrolizumab compared with Brentuximab vedotin; about 4.9 months longer for half the group.
  • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
  • Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.48 to 0.88).
  • This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
  • These results apply to the people the trial enrolled: Relapsed/refractory classical Hodgkin lymphoma: pembrolizumab vs brentuximab vedotin. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

304 participants enrolled.

Progression-free survival (median)primary
HR 0.65 (0.48–0.88) · p = 0.0027
Pembrolizumab
13.2 mo
Brentuximab vedotin
8.3 mo
Source
EndpointArmnValueHR (95% CI)pSource
Progression-free survival (median)primaryPembrolizumab15113.2 months0.65 (0.48–0.88)0.0027link
Brentuximab vedotin1538.3 months

Connected

3top